Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-08
C
Cesar Gentille
Assistant Professor
Also affiliated: Houston Methodist (2020); University of Arkansas Medical Center (2025); Stanford Medicine (2021–2022); Stanford University (2021–2022)
1 h-index
9 pubs
13 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Cesar Gentille's research focuses on clinical outcomes and treatment strategies for hematologic malignancies. His work includes investigating opportunistic infections in patients receiving daratumumab for multiple myeloma and evaluating the efficacy of mogamulizumab in combination therapies for relapsed and refractory Sézary syndrome. Gentille has also studied the association between CAR-T therapy and adverse events like cytokine release syndrome, and its impact on cardiac function. His publications also examine real-world survival data for CAR-T and bispecific T-cell engagers in diffuse large B-cell lymphoma (DLBCL) and analyze rare cases such as chronic neutrophilic leukemia in multiple myeloma patients and uterine DLBCL. Additionally, his research has explored treatment protocols for acute promyelocytic leukemia, including the use of isotretinoin during consolidation phases.
Metrics
- h-index: 1
- Publications: 9
- Citations: 13
Positions
-
Assistant Professor publications 2025–2026University of Arkansas for Medical Sciences Institution web page
Selected Publications
-
Chronic Neutrophilic Leukemia in a Patient With Multiple Myeloma (2026)
-
Isotretinoin Use During Consolidation in Acute Promyelocytic Leukemia Following Standard All-Trans Retinoic Acid (ATRA)-Based Induction: A Case Report (2026)
-
Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026)
-
Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome (2025)
Collaboration Network
Top Collaborators
Jordan Pilkington
University of Arkansas for Medical Sciences
1 shared publication
In database
- Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
Sophia Ly
University of Arkansas for Medical Sciences
1 shared publication
In database
- Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
Delice Kayishunge
University of Arkansas for Medical Sciences
1 shared publication
In database
- Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
Henry K. Wong
University of Arkansas for Medical Sciences
1 shared publication
In database
- Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
Nishanth Thalambedu
University of Arkansas for Medical Sciences
1 shared publication
In database
- Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL
Krishna Vasipalli
Alabama State University (US)
1 shared publication
- Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL
Alan Baltz
University of Arkansas for Medical Sciences
1 shared publication
In database
- Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL
Mamatha Gaddam
University of Arkansas for Medical Sciences
1 shared publication
In database
- Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL
Sravani Gundarlapalli
University of Arkansas for Medical Sciences
1 shared publication
In database
- Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL
Muthu V. Kumaran
Winthrop Rockefeller Foundation (US)
1 shared publication
- Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL
Ankur Varma
University of Arkansas for Medical Sciences
1 shared publication
In database
- Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL
Anushareddy Muddasani
University of Arkansas for Medical Sciences
1 shared publication
In database
- Isotretinoin Use During Consolidation in Acute Promyelocytic Leukemia Following Standard All-Trans Retinoic Acid (ATRA)-Based Induction: A Case Report
Rachel J Hendrix
University of Arkansas for Medical Sciences
1 shared publication
In database
- Isotretinoin Use During Consolidation in Acute Promyelocytic Leukemia Following Standard All-Trans Retinoic Acid (ATRA)-Based Induction: A Case Report
Jennifer Laudadio
University of Arkansas for Medical Sciences
1 shared publication
In database
- Isotretinoin Use During Consolidation in Acute Promyelocytic Leukemia Following Standard All-Trans Retinoic Acid (ATRA)-Based Induction: A Case Report
Nikhil Verma
University of Arkansas for Medical Sciences
1 shared publication
In database
- Chronic Neutrophilic Leukemia in a Patient With Multiple Myeloma
Similar Researchers
Based on overlapping research topics
Tanvi Harishbhai Patel
University of Arkansas for Medical Sciences
CAR-T cell therapy research
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Anup Trikkanad
University of Arkansas for Medical Sciences
CAR-T cell therapy research
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Jaskirat Sethi
University of Arkansas for Medical Sciences
CAR-T cell therapy research
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
N. Jain
University of Arkansas for Medical Sciences
CAR-T cell therapy research
Pharmacological Effects and Toxicity Studies
Medical Case Reports
Mary Price
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Adetayo Odueke
University of Arkansas at Fayetteville
CAR-T cell therapy research
Pharmacological Effects and Toxicity Studies
Medical Case Reports